Navigation Links
Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
Date:1/4/2008

INDIANAPOLIS, Jan. 4 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the fourth quarter and full year of 2007 on Tuesday, January 29, 2008. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

The conference call will be held from 9:00 a.m. to 10:00 a.m. EST. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at http://www.lilly.com. The webcast of the conference call will be available for replay through February 29, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...cancer, constipation and other conditions may soon...f using injections.Scientists in India have develo...s to manage diseases that often require an injecti...nfections. The new gel can also prevent problems c...
...combined efforts to determine the potential health...looked at 20 risk factors.// Some of those include... and hygiene, indoor smoke, childhood sexual abuse...7 percent of premature deaths and 39 percent of to...
...al activity of adults with asthma. Knowing if asth...ing could help health professionals in designing f...the Centers for Disease Control and Prevention con...ctivity levels of adults with asthma. The study in...
..., frequent urination or abnormal periods, uterine ...rous // growths found in the uterus and can range ...e or larger. Now, there’s an improvement to uterin...at’s becoming the procedure of choice for many wom...
Other Medicine News:
(Date:9/3/2008)...SELS, Belgium and GENEVA, Sept. 3 /- ...lestone in CHO based monoclonal antibody,productio...over 31 grams,per liter. This record level was acc...logies: (1) a high-performance stable Selexis CHO,... leading scientists at,Selexis SA using their prop...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans with FDA...Therapeutics, Inc.,announced today that it succes...velopment of the company,s new, innovative low-dos...pany refers to by its internal product,code AG-200...sfully met its,primary endpoint of ovulation suppr...
(Date:9/3/2008)...509 to be Evaluated in Repeat-Dosing Study in Subj...ire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nasda...ase,2 clinical trial (SB-509-801) to evaluate its ... degenerative motor-neuron disease for which there...amo,s drug, SB-509, is an injectable formulation o...
(Date:9/2/2008)...S, September 3 /-, - This ...ased the Risk,of Stroke by 34% in Patients With At...tely Treated by Antithrombotic Therapy, The resul...ENA study,were presented today at the clinical tri...ology congress 2008, in Munich, Germany. Previous ...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Amira Pharmaceuticals Appoints First Vice President of Development 5214 1Amira Pharmaceuticals Appoints First Vice President of Development 5214 2Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 1Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 1Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 3Spinal Stem Cells Offer Hope Against Back Pain 5205 1Spinal Stem Cells Offer Hope Against Back Pain 5205 2
...New Studies Confirm That Fusion Proteins Made by C...dies Demonstrate Increased,Anti-Tumor Activity Wit..., Calif., April 18, 2007,/PRNewswire-FirstCall/ --...e biopharmaceutical company developing targeted,mo...d hepatitis C,virus infection, today reported that...
...AITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2...edImmune, Inc. today,announced data from a preclin...rcinoembryonal antigen (CEA) were shown to prevent...etastases. An,established marker for tumor progres... and other human carcinomas. These data,presented...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 2Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 3Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5
...ries Freezing Stages fit easily onto most microtom...arts and need only the AC supply and a trickle of ...ediately and can be maintained indefinitely. Stag...g temperatures can be set for different kinds of t...
ELISA kit for the quantitative determination of autoantibodies to glutamic acid decarboxylase (GAD65) in serum
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum
RIA kit for the quantitative determination of autoantibodies to insulin in serum
Medicine Products: